The DOI matches its Crossref record; 445 of the 445 references it cites were found in a registry or an index.
Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting
Open accessAbstract
With cardiovascular disease being the leading cause of morbidity and mortality worldwide, effective and cost-efficient therapies to reduce cardiovascular risk are highly needed. Lipids and lipoprotein particles crucially contribute to atherosclerosis as underlying pathology of cardiovascular disease and influence inflammatory processes as well as function of leukocytes, vascular and cardiac cells, thereby impacting on vessels and heart. Statins form the first-line therapy with the aim to block cholesterol synthesis, but additional lipid-lowering drugs are sometimes needed to achieve low-density lipoprotein (LDL) cholesterol target values. Furthermore, beyond LDL cholesterol, also other lipid mediators contribute to cardiovascular risk. This review comprehensively discusses low- and high-density lipoprotein cholesterol, lipoprotein (a), triglycerides as well as fatty acids and derivatives in the context of cardiovascular disease, providing mechanistic insights into their role in pathological processes impacting on cardiovascular disease. Also, an overview of applied as well as emerging therapeutic strategies to reduce lipid-induced cardiovascular burden is provided.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–445 of 445
Hippe, D. S., Phan, B. A. P., Sun, J., Isquith, D. A., O’Brien, K. D., Crouse, J. R., Anderson, T. J., Huston, J., Marcovina, S. M., Hatsukami, T. S., et al. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310368 · Cited by 41
Westerink, J., Deanfield, J. E., Imholz, B. P. M., Spiering, W., Basart, D. C. G., Coll, B., Kastelein, J. J. P., & Visseren, F. L. J. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.11.028 · Cited by 40
Statins in homozygous familial hypercholesterolemia
Marais, A. D., Blom, D. J., & Firth, J. C. (2002) · Current Atherosclerosis Reports · doi:10.1007/s11883-002-0058-7 · Cited by 40
Severely altered cholesterol homeostasis in macrophages lacking apoE and SR-BI
Yancey, P. G., W. Gray, J., Hong, Y., Griffin, E. E., Cox, B. E., Babaev, V. R., Sergio, F., & Linton, M. F. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m600539-jlr200 · Cited by 40
Bilheimer, D. W., Grundy, S. M., Brown, M. S., & Goldstein, J. L. (1983) · PubMed · Cited by 40
Ząbczyk, M., Hońdo, Ł., Krzek, M., et al. (2012) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e32835a083c · Cited by 39
Leipold, R. J., Raal, F. J., Ishak, J., Hovingh, K., & Phillips, H. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317730473 · Cited by 38
Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?
Mani, P., & Rohatgi, A. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0521-x · Cited by 37
Proteolysis of Apolipoprotein A-I by Secretory Phospholipase A2
Cavigiolio, G., & Jayaraman, S. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.525717 · Cited by 37
Serum Amyloid A Facilitates Early Lesion Development in Ldlr −/− Mice
Krishack, P. A., Bhanvadia, C. V., Lukens, J. R., Sontag, T. J., de Beer, M. C., Getz, G. S., & Reardon, C. A. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.001858 · Cited by 37
Serum amyloid A impairs the antiinflammatory properties of HDL
Han, C. Y., Tang, C., Guevara, M. E., Hao, W., Wietecha, T., Shao, B., Subramanian, S., Omer, M., Wang, S., O’Brien, K. D., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86401 · Cited by 37
Nguyen, S. D., Maaninka, K., Lappalainen, J., Nurmi, K., Metso, J., Öörni, K., Navab, M., Fogelman, A. M., Jauhiainen, M., Lee‐Rueckert, M., et al. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306827 · Cited by 35
Feuerborn, R., Besser, M., Potì, F., Burkhardt, R., Weißen-Plenz, G., Ceglarek, U., Simoni, M., Proia, R. L., Freise, H., & Nofer, J. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1666870 · Cited by 35
Decrease in membrane phospholipids unsaturation correlates with myocardial diastolic dysfunction
Yamamoto, T., Endo, J., Kataoka, M., Matsuhashi, T., Katsumata, Y., Shirakawa, K., Yoshida, N., Isobe, S., Moriyama, H., Goto, S., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0208396 · Cited by 32
Gouni‐Berthold, I., Alexander, V. J., DIGENIO, A. G., Dufour, R., Steinhagen‐Thiessen, E., Martin, S., Moriarty, P. M., Hughes, S. G., Witztum, J. L., Gaudet, D., et al. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.04.038 · Cited by 31
Morikawa, K., Adachi, S., Maejima, Y., Tamamori‐Adachi, M., Suzuki, J., Kitajima, S., Ito, H., & Isobe, M. (2006) · Life Sciences · doi:10.1016/j.lfs.2006.04.005 · Cited by 30
Liu, Q., Matthan, N. R., Manson, J. E., Howard, B. V., Tinker, L. F., Neuhouser, M. L., Horn, L. V., Rossouw, J. E., Allison, M., Martin, L. W., et al. (2019) · Nutrients · doi:10.3390/nu11071672 · Cited by 28
Fatty acid-induced atherogenic changes in extracellular matrix proteoglycans
Rodrı́guez-Lee, M., Bondjers, G., & Camejo, G. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3282ef534f · Cited by 27
Kawagoe, Y., Hattori, Y., Nakano, A., Aoki, C., Tanaka, S., Ohta, S., Iijima, T., Tomizawa, A., Jojima, T., Kase, H., et al. (2011) · Endocrine journal · doi:10.1507/endocrj.k10e-289 · Cited by 26
Franco, A. G., Sandri, S., & Čampa, A. (2011) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/s0074-02762011000800014 · Cited by 26
Hydrolysis of phospholipids by purified milk lipoprotein lipase
Lambert, D., Smith, L. C., Pownall, H. J., Sparrow, J. T., Nicolas, J., & Gotto, A. M. (2000) · Clinica Chimica Acta · doi:10.1016/s0009-8981(99)00193-x · Cited by 25
Reinders, I., Murphy, R. A., Song, X., Mitchell, G. F., Visser, M., Cotch, M. F., Garcia, M. E., Launer, L. J., Eiríksdóttir, G., Gudnason, V. G., et al. (2015) · Journal of Nutrition · doi:10.3945/jn.115.212282 · Cited by 25
de Carvalho, L. S. F., Virginio, V. W., Panzoldo, N. B., Figueiredo, V. N., dos Santos, S. N., Modolo, R., Andrade, J. M., Silva, J. C. Q. E., Nadruz, W., de Faria, E. C., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.10.104 · Cited by 25
HDL modification: recent developments and their relevance to atherosclerotic cardiovascular disease
Wilkins, J. T., & Seckler, H. S. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000571 · Cited by 25
Dinnes, D. L. M., White, M. Y., Kockx, M., Traini, M. D., Hsieh, V., Kim, M., Hou, L., Jessup, W., Rye, K., Thaysen‐Andersen, M., et al. (2016) · The FASEB Journal · doi:10.1096/fj.201600508r · Cited by 24
Zheng, X., & Hu, S. (2005) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2005.00105.x · Cited by 23
Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?
Filippatos, T. D., Christopoulou, E. C., & Elisaf, M. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000523 · Cited by 22
Wang, D., Liu, H., Yan, L., Zhang, Y.-P., Guan, X., Xu, Z., Jia, Y.-H., & Li, Y. (2013) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20130400 · Cited by 21
Detection of chymase-digested C-terminally truncated apolipoprotein A-I in normal human serum
Usami, Y., Matsuda, K., Sugano, M., Ishimine, N., Kurihara, Y., Sumida, T., Yamauchi, K., & Tozuka, M. (2011) · Journal of Immunological Methods · doi:10.1016/j.jim.2011.04.002 · Cited by 21
Yang, H. M., Li, N., Zhou, Y., Xiao, Z., Tian, H., Hu, M., & Li, S. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s213968 · Cited by 21
Mayer, F., Binder, C. J., Krychtiuk, K. A., Schillinger, M., Minar, E., & Hoke, M. (2019) · European Journal of Clinical Investigation · doi:10.1111/eci.13095 · Cited by 19
Chaiyasothi, T., Nathisuwan, S., Dilokthornsakul, P., Vathesatogkit, P., Thakkinstian, A., Reid, C. M., Wongcharoen, W., & Chaiyakunapruk, N. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00547 · Cited by 19
Nishikimi, T., Tadokoro, K., Wang, X., Mori, Y., Asakawa, H., Akimoto, K., Yoshihara, F., Horio, T., Minamino, N., & Matsuoka, H. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02453-6 · Cited by 17
Dong, M., Jiang, X., Liao, J. K., & Yan, B. P. (2013) · Clinical Cardiology · doi:10.1002/clc.22118 · Cited by 15
Santos, R. D. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310675 · Cited by 15
Adverse interaction between HDL and the mass of myocardial infarction
Soares, A., de Carvalho, L. S. F., Bonilha, I., Virginio, V. W., Nadruz, W., Coelho‐Filho, O. R., Silva, J. C. Q. E., Petrucci, O., & Sposito, A. C. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.12.002 · Cited by 15
Platelet Acetyl-CoA Carboxylase Phosphorylation
Kautbally, S., Lepropre, S., Onselaer, M.-B., Lerigoleur, A., Ginion, A., de Meester, C., Ambroise, J., Boudjeltia, K. Z., Octave, M., Wéra, O., et al. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.04.005 · Cited by 15
Steffen, B. T., Guan, W., Stein, J. H., Tattersall, M. C., Kaufman, J. D., Sandfort, V., Szklo, M., & Tsai, M. Y. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310366 · Cited by 14
Gelrud, A., DIGENIO, A. G., Alexander, V. J., Williams, K. R., Hsieh, A., Gouni‐Berthold, I., Bruckert, É., Stroes, E. S. G., Geary, R. S., Hughes, S. G., et al. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.03.032 · Cited by 14
Camejo, G. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.02.005 · Cited by 13
Meta-analysis Comparing Combined Use of Eicosapentaenoic Acid and Statin to Statin Alone
Doshi, R. P., Kumar, A., Thakkar, S. J., Shariff, M., Adalja, D., Doshi, A., Taha, M., Gupta, R., Desai, R., Shah, J., et al. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.10.009 · Cited by 13
Challenges in Interpreting the Lipid-Lowering Trials
Návar, A. M., & Peterson, E. D. (2018) · JAMA · doi:10.1001/jama.2018.4041 · Cited by 11
Takase, H., Tanaka, M., Nakamura, Y., Morita, S., Yamada, T., & Mukai, T. (2019) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2019.03.001 · Cited by 9
Cohen, J. C., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng0305-328c · Cited by 5
Gelrud, A., DIGENIO, A. G., Alexander, V. J., Williams, K. R., Hsieh, A., Gouni-Berthold, I., Bruckert, É., Stroes, E. S. G., Geary, R. S., Hughes, S., et al. (2018) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2018.04.476 · Cited by 5
Cited by
Diabetic vascular diseases: molecular mechanisms and therapeutic strategies
Li, Y., Liu, Y., Liu, S., Gao, M., Wang, W., Chen, K., Huang, L., & Liu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01400-z · Cited by 704
Signaling pathways of chronic kidney diseases, implications for therapeutics
Yuan, Q., Tang, B., & Zhang, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01036-5 · Cited by 453
Ketogenic diet and multiple health outcomes: an umbrella review of meta-analysis
Chen, S., Su, X., Feng, Y., Li, R., Liao, M., Fan, L., Liu, J., Chen, S., Zhang, S., Cai, J., et al. (2023) · Nutrients · doi:10.3390/nu15194161 · Cited by 41
Insights into the molecular underpinning of type 2 diabetes complications
Singh, A., Bocher, O., & Zeggini, E. (2025) · Human Molecular Genetics · doi:10.1093/hmg/ddae203 · Cited by 10
Metadata
- Authors
- Soppert, J., Lehrke, M., Marx, N., Jankowski, J., & Noels, H.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2020
- Volume
- 159
- Pages
- 4-33
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W3044870380
- Cited by
- 407
- References
- 445
- FWCI
- 8.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.